Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Progression risk stratification of asymptomatic WM

Romanos Sklavenitis-Pistofidis • 14 Sep 2019
IMW 2019
Rare Diseases Waldenström’s Macroglobulinemia

Romanos Sklavenitis-Pistofidis, MD Dana-Farber Cancer Institute, Boston, MA, gives a brief outline of his work into the progression risk stratification of asymptomatic Waldenstrom macroglobulinemiaspeaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Romanos Sklavenitis-Pistofidis

1:44
Smoldering myeloma: the challenges of 'watch and wait' versus early intervention
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
3:25
Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
3:38
Identifying immune biomarkers of progression in patients with HR-SMM treated with immunotherapy
Romanos Sklavenitis-Pistofidis • 16 Dec 2022
6:33
Risk stratification model for asymptomatic Waldenström’s macroglobulinemia
Romanos Sklavenitis-Pistofidis • 1 Nov 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals